Claims for Patent: 8,722,865

Summary for Patent: 8,722,865

Title:	Isolated genomic polynucleotide fragments from the p15 region of isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4)
Abstract:	Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.
Inventor(s):	Ryan; James (Augusta, GA)
Assignee:	Kyoger, LLC (N/A)
Application Number:	13/244,468
Patent Claims:	1. An isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c): a reverse strand of the polynucleotides of (a) or (b), wherein the isolated polynucleotide is modified. 2. A nucleic acid construct comprising the polynucleotide of claim 1. 3. An expression vector comprising the polynucleotide of claim 1. 4. A recombinant host cell comprising the polynucleotide of claim 1. 5. A method for obtaining human tumor suppressing subtransferable candidate 4 (TSSC4) comprising: (a) culturing the recombinant host cell of claim 4 under conditions that provide for the obtaining of human tumor suppressing subtransferable candidate 4 (TSSC4) and (b) recovering said human tumor suppressing subtransferable candidate 4 (TSSC4). 6. An isolated polynucleotide at least 50 nucleotides in length identical to a region of SEQ ID NO:12, said region selected from the group consisting of a 5'-noncoding region, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein the isolated polynucleotide is modified. 7. The isolated polynucleotide of claim 6, wherein said 5'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12 and said 3'-non-coding region consists of nucleotides 14968-14972 of SEQ ID NO:12. 8. A composition comprising the polynucleotide of claim 1 and a carrier or diluent. 9. A composition comprising the polynucleotide of claim 6 and a carrier or diluent. 10. A kit comprising the polynucleotide of claim 1. 11. A kit comprising the polynucleotide of claim 6. 12. A method for preparing an antibody specific to human tumor suppressing subtransferable candidate 4 (TSSC4) comprising: (a) obtaining a polypeptide according to the method of claim 5; (b) optionally conjugating said polypeptide to a carrier protein; (c) immunizing a host animal with said polypeptide or polypeptide-carrier protein conjugate of step (b) with an adjuvant and (d) obtaining antibody from said immunized host animal. 13. A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 1 effective to prevent, treat or ameliorate said medical condition. 14. A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 6 effective to prevent, treat or ameliorate said medical condition. 15. A method of identifying variants of SEQ ID NO:12 or its complementary sequence comprising (a) isolating genomic DNA from a subject and (b) determining the presence or absence of a variant in said genomic DNA using the polynucleotide of claim 6. 16. A method for detecting the presence or absence of a nucleic acid sequence of SEQ ID NO:12 or its complementary sequence in a sample, said method comprising contacting the sample with the polynucleotide of claim 6. 17. A method of detecting the presence or absence of a variant of human tumor suppressing subtransferable candidate 4 (TSSC4) in a sample using the polynucleotide of claim 1. 18. A method of detecting the presence or absence of a nucleotide variant of SEQ ID NO:12, or its complementary sequence comprising: (a) isolating genomic DNA from a subject, and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide acid sequence of SEQ ID NO:12 with the nucleotide sequence of the isolated genomic DNA of (a) and establishing if and where a difference occurs between the two nucleic acid sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:12, or its complementary sequence. 19. A method for obtaining the polynucleotide of claim 1 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes ace at least 50 nucleotides in length identical to a region of SEQ ID NO: 12, said region selected from the group consisting of a 5'-noncoding region, an intron, 3'-non-coding region and a contiguous coding and non-coding, nucleic acid sequence region of SEQ ID NO: 12 reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide. 20. A method for obtaining the polynucleotide of claim 6 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes are at least 50 nucleotides in length identical to a region of SEQ ID NO: 12 said region selected from the group consisting of a 5'-noncoding region, an intron, a 3'-non-coding region and contiguous coding and non-coding sequence region of SEQ ID NO:12, or reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide. 21. The polynucleotide according to claim 1, wherein said polynucleotide is DNA or RNA. 22. An isolated polynucleotide consisting of a 5'-noncoding region, a 3'-non-coding region or a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12, or reverse strand of said polynucleotide, wherein the 5'-noncoding region consists of nucleotides 14969-15540 of SEQ ID NO:12 and the 3'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12, wherein the isolated polynucleotide is modified. 23. An isolated polynucleotide fragment of the isolated polynucleotide of claim 22, wherein said fragment is at least 500 nucleotides in length. 24. The method according to claim 19, wherein said polynucleotide is DNA or RNA. 25. The method according to claim 20, wherein said polynucleotide is DNA or RNA. 26. The polynucleotide of claim 6, wherein said polynucleotide is DNA or RNA. 27. The polynucleotide of claim 22, wherein said polynucleotide is DNA or RNA. 28. A kit comprising the polynucleotide of claim 22. 29. A nucleic acid construct comprising an isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c) a reverse strand of the polynucleotides of (a) or (b). 30. A recombinant expression vector comprising the nucleic acid construct of claim 29. 31. A recombinant host cell comprising the nucleic acid construct of claim 29. 32. A kit comprising at least one of: (i) an isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c) a reverse strand of the polynucleotides of (a) or (b), wherein said isolated polynucleotide is optionally labeled with a detectable substance, (ii) an isolated polynucleotide at least 50 nucleotides in length identical to a region of SEQ ID NO:12, said region selected from the group consisting of a 5'-non-coding region, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein said isolated polynucleotide is optionally labeled with a detectable substance, or (iii) an isolated polynucleotide consisting of a 5'-non-coding region, a 3'-non-coding region or a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein the 5'-non-coding region consists of nucleotides 14969-15540 of SEQ ID NO:12 and the 3'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12, wherein said isolated polynucleotide is optionally labeled with a detectable substance.

Details for Patent 8,722,865

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-10-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-10-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-10-31